The Cooper (STU:CP60) Total Liabilities : €3,955 Mil (As of Apr. 2024)

View and export this data going back to 1983. Start your Free Trial

What is The Cooper Total Liabilities?

The Cooper's Total Liabilities for the quarter that ended in Apr. 2024 was €3,955 Mil.

The Cooper's quarterly Total Liabilities increased from Oct. 2023 (€3,890.18 Mil) to Jan. 2024 (€3,981.64 Mil) but then declined from Jan. 2024 (€3,981.64 Mil) to Apr. 2024 (€3,954.94 Mil).

The Cooper's annual Total Liabilities increased from Oct. 2021 (€2,296.54 Mil) to Oct. 2022 (€4,382.36 Mil) but then declined from Oct. 2022 (€4,382.36 Mil) to Oct. 2023 (€3,890.18 Mil).

The Cooper Total Liabilities Historical Data

The historical data trend for The Cooper's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

The Cooper Total Liabilities Chart

The Cooper Annual Data

Trend

Oct14

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Total Liabilities

Get a 7-Day Free Trial

2,391.89

2,475.80

2,296.54

4,382.36

3,890.18

The Cooper Quarterly Data
	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24
Total Liabilities	Get a 7-Day Free Trial															3,795.29	3,768.60	3,890.18	3,981.64	3,954.94

The Cooper Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

The Cooper's Total Liabilities for the fiscal year that ended in Oct. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	917.643	+	(2390.039	+	85.419
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	270.558	+	226.522)
	=	3,890

Total Liabilities	=	Total Assets (A: Oct. 2023 )	-	Total Equity (A: Oct. 2023 )
	=	11040.978	-	7150.797
	=	3,890

The Cooper's Total Liabilities for the quarter that ended in Apr. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	887.73	+	(2489.652	+	313.99
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	263.57	+	0)
	=	3,955

Total Liabilities	=	Total Assets (Q: Apr. 2024 )	-	Total Equity (Q: Apr. 2024 )
	=	11228.177	-	7273.235
	=	3,955

The Cooper Total Liabilities Related Terms

Thank you for viewing the detailed overview of The Cooper's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

The Cooper (STU:CP60) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » The Cooper Companies Inc (STU:CP60) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

COO:USA COO:Mexico C1OO34:Brazil

Address

6101 Bollinger Canyon Road, Suite 500, San Ramon, CA, USA, 94583

Website

https://www.coopercos.com

The Cooper Companies is one of the largest eye care companies in the U.S. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business and is composed of a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and clariti, Cooper controls roughly a quarter of the U.S. contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the U.S., and controls 17% of the U.S. IUD market.

The Cooper (STU:CP60) Headlines

No Headlines